<DOC>
	<DOCNO>NCT00476983</DOCNO>
	<brief_summary>Pharmacokinetic long term efficacy TDF SQV film coat tablet 1500/100mg daily plus TDF/FTC300/200mg daily .</brief_summary>
	<brief_title>Pharmacokinetic Efficacy SQV/r 1500/100 Plus Tenofovir/Emtricitabine 300/200 mg</brief_title>
	<detailed_description>This study perform patient previously treat SQV /r 1000/100mg twice daily Lopinavir/r plus TDF/FTC daily part Gemini study . After 48 week study , patient treat SQV film coat tablet 1500/100mg daily plus TDF/FTC300/200mg daily good CD4 VL outcomes . In study , would like evaluate once-daily dose SQV use SQV- SQV film coat tablet 1500/ritonavir 100mg combination TDF/FTC300/200mg daily . We believe PK parameter SQV give 1500mg daily equivalent 1000mg twice daily dose combine RTV TDF/FTC300/200mg OD , daily regimen well safety , tolerability profile twice daily regimen maintain good CD4 VL outcome</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1. write informed consent 2 . All adult HIV patient previously include Gemini study currently enrol HIVNAT 006 treat SQV /r 1500/100 mg OD plus tenofovir/emtricitabine ( TDF/FTC ) 300/200 mg daily 1 . Inability understand nature extent study procedure require . 2 . ALT/ AST 5x upper limit 3 . Relevant history current condition , illness might interfere drug absorption , distribution , metabolism excretion . 4 . Use concomitant medication may interfere pharmacokinetics saquinavir , ritonavir , tenofovir emtricitabine 5 . History sensitivity/idiosyncrasy drug chemically related compound may employ study . 6 . Active drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>saquinavir/ritonavir 1500/100 mg daily</keyword>
</DOC>